Skip to main content

RNA Virus Infections clinical trials at UC Health

1 research study open to eligible people

Showing trials for
  • Cell therapy to Treat Patients with COVID-19

    open to eligible people ages 18 years and up

    This study is a Phase 1 / 2 trial to determine the safety and efficacy of CYNK-001, an immunotherapy containing Natural Killer (NK) cells derived from human placental CD34+ cells and culture-expanded, in hospitalized patients with moderate COVID-19 disease.

    at UC Davis UC Irvine

Last updated: